Accera Reaches 75% Enrollment in the Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
July 14, 2015
BROOMFIELD, Colo., July 14, 2015 /PRNewswire/ — Accera, Inc. today announced that it has achieved 75% enrollment for its NOURISH AD Phase 3 clinical study of AC-1204 for the treatment of Alzheimer's disease. The study has a total planned enrollment of approximately 480 patients and is the first of two Phase 3 trials of AC-1204, an investigational new drug designed to address the metabolic defect of the brain observed in Alzheimer's patients.
"The NOURISH AD trial is progressing well, and we expect to complete enrollment mid-next year," said Accera's President and CEO, Dr. Charles Stacey. cThe repeated failure of pipeline drugs for Alzheimer's disease emphasizes the need to explore new mechanisms in order to identify new options for patients. The NOURISH AD study represents a differentiated approach to tackling this disease."
"Instead of addressing amyloid or tau, AC-1204 addresses the metabolic defects seen in the disease," added Samuel Henderson, Ph.D., Accera's vice president of research and development and the study's director. "The only way we can beat Alzheimer's is by testing new drugs in studies like NOURISH AD. We are grateful for the support of all of the patients, caregivers and investigators who have joined us in the effort to find new treatments."
About the NOURISH AD Phase 3 Clinical Study
NOURISH AD is a 26-week, double-blind, randomized, placebo-controlled, parallel-group study investigating the effects of daily administration of AC-1204 in subjects with mild to moderate Alzheimer's disease, with an optional 26-week open-label extension. Conducted at up to 90 sites, the study is currently enrolling patients with an anticipated total of approximately 480 enrolled. The primary and key secondary endpoints will examine the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and global function as measured by the Alzheimer's Disease Study Cooperative Study – Clinicial Global Impression of Change (ADCS-CGIC) after 26 weeks among non-carriers of the epsilon 4 variant of the gene apolipoprotein E (APOE4). The study will also evaluate activities of daily living, resource utilization and quality of life among subjects with mild-to-moderate Alzheimer's.
For more information, visit https://www.AD-trial.com